zolmitriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2869 139264-17-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zolmitriptan
  • zipton
  • zominat
  • zomigoro
  • 311C90
an antimigraine compound; a serotonin (5HT)-1D receptor agonist
  • Molecular weight: 287.36
  • Formula: C16H21N3O2
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 57.36
  • ALOGS: -3.18
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg N
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.50 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.634 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.882 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.365 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.875 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 86.130 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 81.500 % High 1
herg hERG pIC50 4.108 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.002 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.027 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 88.630 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIM2,PRKDC,SIK2,TEK 23
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.042 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.622 High 1
mh-clint Mouse hepatocyte intrinsic clearance 4.742 High 1
mppb Mouse plasma protein binding (% unbound) 84.120 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 4.093 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 90.360 % High 1
rat-kpuu-brain Rat brain Kpuu 0.015 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.119 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.930 % High 1
rppb Rat plasma protein binding (% unbound) 86.620 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 944.061 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 25, 1997 FDA IPR

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Swollen tongue 329.54 17.60 148 11997 45808 90570494
Dysphonia 299.38 17.60 153 11992 62931 90553371
Angioedema 292.45 17.60 152 11993 64724 90551578
Drug ineffective for unapproved indication 266.05 17.60 144 12001 66500 90549802
Swelling face 262.89 17.60 153 11992 81199 90535103
Headache 171.66 17.60 364 11781 862382 89753920
Drug intolerance 130.92 17.60 223 11922 447368 90168934
Migraine 122.69 17.60 139 12006 190253 90426049
Vascular malformation 107.47 17.60 24 12121 728 90615574
Paranasal cyst 105.70 17.60 24 12121 786 90615516
Medication overuse headache 105.52 17.60 27 12118 1474 90614828
Mastoiditis 102.66 17.60 27 12118 1643 90614659
Skin candida 64.85 17.60 19 12126 1722 90614580
Hypersensitivity 60.76 17.60 165 11980 454512 90161790
Otitis media 58.84 17.60 24 12121 5846 90610456
Monocyte count abnormal 51.93 17.60 11 12134 259 90616043
Antibody test positive 50.91 17.60 18 12127 2971 90613331
Dyspnoea exertional 46.84 17.60 53 12092 72235 90544067
Urticaria chronic 40.04 17.60 11 12134 790 90615512
Lymphocyte count abnormal 38.95 17.60 11 12134 874 90615428
Infrequent bowel movements 37.17 17.60 12 12133 1502 90614800
Reversible cerebral vasoconstriction syndrome 35.06 17.60 15 12130 4115 90612187
Temperature intolerance 34.53 17.60 21 12124 12009 90604293
Off label use 33.54 17.60 257 11888 1101995 89514307
Vertigo 33.53 17.60 44 12101 69767 90546535
Congenital hypoplasia of depressor angularis oris muscle 31.83 17.60 6 12139 76 90616226
Disturbance in attention 31.29 17.60 35 12110 47074 90569228
Arthropathy 30.55 17.60 6 12139 366236 90250066
Nervous system disorder 29.69 17.60 24 12121 21569 90594733
Blood thyroid stimulating hormone normal 29.40 17.60 6 12139 117 90616185
Arteriospasm coronary 29.10 17.60 14 12131 5036 90611266
Colitis ischaemic 29.05 17.60 19 12126 12327 90603975
Stress 28.32 17.60 44 12101 81351 90534951
Blood immunoglobulin E increased 27.74 17.60 13 12132 4412 90611890
Polymenorrhagia 27.52 17.60 5 12140 51 90616251
General physical health deterioration 27.24 17.60 7 12138 355108 90261194
Oligohydramnios 27.13 17.60 15 12130 7186 90609116
Drug abuser 26.97 17.60 11 12134 2679 90613623
Myalgia 26.83 17.60 67 12078 175058 90441244
Tuberculosis 26.36 17.60 18 12127 12531 90603771
Stomatitis 26.34 17.60 3 12142 274695 90341607
Serotonin syndrome 24.91 17.60 28 12117 37859 90578443
Muscle discomfort 24.06 17.60 6 12139 295 90616007
Burns third degree 23.77 17.60 6 12139 310 90615992
Tuberculin test positive 23.52 17.60 11 12134 3714 90612588
Therapy partial responder 23.16 17.60 21 12124 22022 90594280
Thunderclap headache 22.86 17.60 6 12139 362 90615940
Aortic valve disease 22.52 17.60 8 12137 1338 90614964
Neutropenic sepsis 22.52 17.60 19 12126 18111 90598191
Oral herpes 22.42 17.60 25 12120 33499 90582803
Anaphylactic reaction 22.08 17.60 41 12104 87483 90528819
Depression 21.93 17.60 89 12056 300512 90315790
Blister 21.63 17.60 4 12141 254994 90361308
Paraesthesia ear 21.57 17.60 6 12139 451 90615851
Vitreous detachment 21.39 17.60 9 12136 2369 90613933
Systemic lupus erythematosus 21.24 17.60 11 12134 361885 90254417
Infusion related reaction 21.20 17.60 15 12130 416765 90199537
Hepatic enzyme increased 21.12 17.60 11 12134 360725 90255577
Tremor 20.78 17.60 56 12089 153117 90463185
Palpitations 20.61 17.60 52 12093 136676 90479626
Mouth ulceration 20.45 17.60 26 12119 39948 90576354
Product use in unapproved indication 20.28 17.60 94 12051 336142 90280160
Dizziness 19.29 17.60 140 12005 589144 90027158
Forced expiratory volume decreased 18.92 17.60 11 12134 5797 90610505
Constipation 18.87 17.60 81 12064 280314 90335988
Insomnia 18.49 17.60 91 12054 333383 90282919
Pneumonia 18.47 17.60 36 12109 638023 89978279
Dust allergy 18.05 17.60 6 12139 823 90615479
Broad ligament tear 17.92 17.60 3 12142 18 90616284
Cluster headache 17.85 17.60 6 12139 851 90615451

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Paraesthesia 72.45 28.16 39 1360 73420 42546516
Therapy partial responder 66.84 28.16 25 1374 19996 42599940
Drug abuse 57.16 28.16 38 1361 104733 42515203
Insomnia 52.99 28.16 38 1361 118215 42501721
Intentional product misuse 37.47 28.16 24 1375 61876 42558060
Craniosynostosis 36.38 28.16 7 1392 429 42619507
Medication overuse headache 34.25 28.16 6 1393 218 42619718
Migraine 32.18 28.16 16 1383 25398 42594538

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Swollen tongue 333.52 16.60 151 11581 60211 110517356
Dysphonia 309.37 16.60 154 11578 75775 110501792
Swelling face 286.53 16.60 156 11576 92165 110485402
Angioedema 274.36 16.60 155 11577 98345 110479222
Drug ineffective for unapproved indication 254.89 16.60 150 11582 102688 110474879
Headache 206.70 16.60 349 11383 882028 109695539
Drug intolerance 168.35 16.60 211 11521 406301 110171266
Migraine 130.64 16.60 123 11609 171529 110406038
Medication overuse headache 126.15 16.60 30 11702 1533 110576034
Vascular malformation 116.82 16.60 25 11707 789 110576778
Paranasal cyst 114.21 16.60 25 11707 879 110576688
Mastoiditis 101.56 16.60 28 11704 2583 110574984
Hypersensitivity 99.57 16.60 164 11568 403834 110173733
Therapy partial responder 68.70 16.60 45 11687 37016 110540551
Otitis media 62.09 16.60 25 11707 7451 110570116
Skin candida 59.46 16.60 18 11714 2310 110575257
Insomnia 44.66 16.60 110 11622 360480 110217087
Off label use 40.30 16.60 284 11448 1499901 109077666
Disturbance in attention 38.84 16.60 40 11692 61955 110515612
Burns third degree 37.39 16.60 9 11723 484 110577083
Reversible cerebral vasoconstriction syndrome 36.38 16.60 15 11717 4746 110572821
Product use in unapproved indication 30.94 16.60 111 11621 447266 110130301
Blood thyroid stimulating hormone normal 30.70 16.60 6 11726 119 110577448
Renal infarct 30.44 16.60 12 11720 3383 110574184
Arteriospasm coronary 29.90 16.60 16 11716 9084 110568483
Polymenorrhagia 28.77 16.60 5 11727 50 110577517
Antibody test positive 27.88 16.60 11 11721 3109 110574458
Stress 26.16 16.60 43 11689 105305 110472262
Tuberculin test positive 26.15 16.60 11 11721 3657 110573910
Depression 25.67 16.60 83 11649 317252 110260315
Drug abuser 25.06 16.60 12 11720 5397 110572170
Drug abuse 25.04 16.60 57 11675 177354 110400213
Myalgia 24.54 16.60 65 11667 222316 110355251
Colitis ischaemic 24.53 16.60 18 11714 17732 110559835
Paraesthesia 23.89 16.60 74 11658 276447 110301120
Palpitations 23.42 16.60 52 11680 159160 110418407
Muscle discomfort 22.74 16.60 6 11726 468 110577099
Nervous system disorder 22.69 16.60 22 11710 31699 110545868
Vertigo 22.30 16.60 36 11696 86834 110490733
Paraesthesia ear 22.02 16.60 6 11726 529 110577038
Thunderclap headache 21.56 16.60 6 11726 572 110576995
Blood immunoglobulin E increased 21.39 16.60 12 11720 7470 110570097
Temperature intolerance 21.23 16.60 15 11717 13935 110563632
Tremor 21.19 16.60 58 11674 202174 110375393
Aortic valve disease 20.42 16.60 8 11724 2219 110575348
Pneumonia 20.24 16.60 39 11693 876675 109700892
Throat tightness 19.88 16.60 21 11711 33468 110544099
Febrile neutropenia 19.11 16.60 5 11727 316762 110260805
Vitreous detachment 19.03 16.60 8 11724 2657 110574910
Drug ineffective 19.01 16.60 245 11487 1520295 109057272
Stomatitis 18.93 16.60 3 11729 270239 110307328
Mouth ulceration 18.26 16.60 24 11708 48114 110529453
Trigemino-cardiac reflex 18.08 16.60 5 11727 466 110577101
Meningoencephalitis bacterial 18.07 16.60 5 11727 467 110577100
Bronchial obstruction 17.92 16.60 8 11724 3071 110574496
Nasal discharge discolouration 17.62 16.60 8 11724 3193 110574374
Nausea 17.54 16.60 204 11528 1235486 109342081
Major depression 17.52 16.60 12 11720 10609 110566958
Stress cardiomyopathy 17.39 16.60 14 11718 15792 110561775
Cluster headache 17.21 16.60 6 11726 1201 110576366
Monoplegia 17.17 16.60 9 11723 4900 110572667
Mitral valve disease 17.10 16.60 8 11724 3417 110574150
Sacroiliitis 17.05 16.60 9 11723 4969 110572598
Coronary artery dissection 17.02 16.60 6 11726 1242 110576325

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC03 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D017366 Serotonin Receptor Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:50514 vasoconstrictor agent

Related Drugs by ATC class:

N02CC Selective serotonin (5HT1) agonists 8 drugs
almotriptaneletriptanfrovatriptanlasmiditannaproxennaratriptanrizatriptansumatriptan

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Cerebral arteriosclerosis contraindication 65312002
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Cerebral ischemia contraindication 287731003
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.47 acidic
pKa2 8.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1E GPCR Ki 7.70 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.60 WOMBAT-PK
5-hydroxytryptamine receptor 1F GPCR Ki 7.45 WOMBAT-PK
D(2) dopamine receptor GPCR Kd 10.40 CHEMBL
D(1A) dopamine receptor GPCR Kd 9.52 CHEMBL
Adrenergic receptor alpha-2 GPCR Kd 8.15 CHEMBL

External reference:

IDSource
4021094 VUID
N0000148550 NUI
D00415 KEGG_DRUG
4021094 VANDF
C0528166 UMLSCUI
CHEBI:10124 CHEBI
CHEMBL1185 ChEMBL_ID
DB00315 DRUGBANK_ID
C089750 MESH_SUPPLEMENTAL_RECORD_UI
60857 PUBCHEM_CID
60 IUPHAR_LIGAND_ID
7408 INN_ID
2FS66TH3YW UNII
135775 RXNORM
52759 MMSL
5712 MMSL
d04253 MMSL
006460 NDDF
108406003 SNOMEDCT_US
363582006 SNOMEDCT_US
2FS66TH3YW INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zolmitriptan Human Prescription Drug Label 1 16571-803 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 16571-804 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 21695-955 SPRAY, METERED 5 mg NASAL NDA 28 sections
Zolmitriptan Human Prescription Drug Label 1 27241-021 TABLET 2.50 mg ORAL ANDA 24 sections
Zolmitriptan Human Prescription Drug Label 1 27241-022 TABLET 5 mg ORAL ANDA 24 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 42291-998 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 42291-999 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 45802-711 SPRAY 5 mg NASAL ANDA 26 sections
Zolmitriptan Human Prescription Drug Label 1 46708-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 46708-463 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan OD Human Prescription Drug Label 1 59746-461 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Zolmitriptan OD Human Prescription Drug Label 1 59746-461 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Zolmitriptan OD Human Prescription Drug Label 1 59746-462 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Zolmitriptan OD Human Prescription Drug Label 1 59746-462 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-130 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-133 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-2383 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 60846-2384 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Zolmitriptan Human Prescription Drug Label 1 62332-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 62332-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 62332-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan Human Prescription Drug Label 1 62332-463 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0101 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0102 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63629-9575 SPRAY 5 mg NASAL ANDA 26 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-083 SPRAY, METERED 2.50 mg NASAL NDA 27 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-084 SPRAY, METERED 5 mg NASAL NDA 27 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 65841-767 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 1 sections